Symbol="IMMX"
AssetType="Common Stock"
Name="Immix Biopharma Inc"
Description="Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology and inflammation in the United States and Australia. The company is headquartered in Los Angeles, California."
CIK="1873835"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="30246900"
EBITDA="-11567278"
PERatio="None"
PEGRatio="None"
BookValue="0.813"
DividendPerShare="0"
DividendYield="0"
EPS="-0.66"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.417"
ReturnOnEquityTTM="-0.731"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.66"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="11"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.156"
EVToRevenue="-"
EVToEBITDA="-0.0128"
Beta="None"
num_52WeekHigh="3.29"
num_52WeekLow="0.68"
num_50DayMovingAverage="2.196"
num_200DayMovingAverage="1.976"
SharesOutstanding="16261800"
DividendDate="None"
ExDividendDate="None"
symbol="IMMX"
open="1.88"
high="1.92"
low="1.75"
price="1.77"
volume="205199.00"
latest_trading_day="2023-08-16"
previous_close="1.86"
change="-0.09"
change_percent="-4.8387%"
aroon_positive_momentum_days="27"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="27"
Volume_recent_avg="240302"
Change_recent_avg="0.01"
Delta_recent_avg="0.19"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="-0.23"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="27"
Aroon_momentum_negative="73"
image_negative_thumbnail_id_1="175"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0001.jpeg"
image_negative_thumbnail_id_2="1114"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0147.jpeg"
image_neutral_thumbnail_id_1="588"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0011.jpeg"
image_neutral_thumbnail_id_2="538"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0061.jpeg"
image_positive_thumbnail_id_1="962"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0124.jpeg"
image_positive_thumbnail_id_2="955"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0117.jpeg"
image_professor_thumbnail_id_1="1179"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0013.jpeg"
image_professor_thumbnail_id_2="1198"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0032.jpeg"
